The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Valuation Is Forecasted For The Pegfilgrastim Biosimilars Market By 2030 Starting From Its 2026 Size?
The pegfilgrastim biosimilars market size has experienced robust expansion in recent years. This market is projected to increase from $1.92 billion in 2025 to $2.04 billion in 2026, registering a compound annual growth rate (CAGR) of 6.3%. The growth observed in the historic period can be attributed to the high cost of originator pegfilgrastim, limited availability of biosimilars, a growing cancer patient population, increasing chemotherapy procedures, and rising awareness of neutropenia management.
The pegfilgrastim biosimilars market is projected to experience robust expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $2.65 billion, demonstrating a compound annual growth rate (CAGR) of 6.7%. This anticipated growth is driven by several factors, including the introduction of novel biosimilars, greater acceptance in supportive oncology treatments, broader reach of hospital and retail pharmacy systems, governmental encouragement for biosimilar utilization, and increased funding for stem cell transplantation procedures. Key trends during this period encompass the growing integration of pegfilgrastim biosimilars within supportive cancer regimens, the broadening of hospital and retail pharmacy distribution avenues, a heightened emphasis on mitigating chemotherapy-induced neutropenia, an increase in hematopoietic and peripheral blood stem cell transplantation uses, and escalating investments in managing chronic and severe congenital neutropenia.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp
What Drivers Are Shaping The Future Growth Of The Pegfilgrastim Biosimilars Market?
The pegfilgrastim biosimilars market is anticipated to be driven by government initiatives focused on the development of biosimilars. Governments globally are prioritizing biosimilar development due to their cost-effectiveness. The US Food and Drug Administration (FDA) launched a Biosimilar Action Plan to enhance treatment options. The Australian government demonstrates its commitment to the Biosimilar Awareness Initiative by providing a grant of $5 million to the Generic and Biosimilar Medicines Association, aiming to facilitate increased general biosimilar education and activities promoting the suitable dispensing, prescription, and use of biosimilar medicines. Therefore, government efforts directed towards biosimilar development contribute to increased production and awareness, which in turn support the growth of the pegfilgrastim biosimilars market.
Which Segment Categories Define The Pegfilgrastim Biosimilars Market?
The pegfilgrastim biosimilars market covered in this report is segmented –
1) By Application: Chemotherapy Treatment, Transplantation, Other Applications
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies
3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes
Subsegments:
1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia
2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia
What Major Market Trends Are Driving Changes In The Pegfilgrastim Biosimilars Market?
Companies operating within the pegfilgrastim biosimilars market are prioritizing technological advancements in biopharmaceuticals, specifically focusing on developing high-quality biosimilars to offer safe, effective, and accessible alternatives to original biologic therapies for cancer patients. These high-quality biosimilars are biologic drugs designed to closely resemble the reference product in terms of structure, function, safety, and efficacy. For example, in February 2023, Fresenius Kabi, a Germany-based healthcare company known for pharmaceuticals and medical technologies, launched Stimufend, its inaugural pegfilgrastim biosimilar, in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with an integrated needle guard. This product signifies a technological step forward, combining advanced biosimilar development with user-friendly delivery to enhance the accessibility of high-quality biologic therapies.
Who Are The Top Companies Competing In The Pegfilgrastim Biosimilars Market?
Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm
Read the full pegfilgrastim biosimilars market report here:
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report
Which Geographic Regions Are Influencing Demand In The Pegfilgrastim Biosimilars Market?
North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pegfilgrastim Biosimilars Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=4015&type=smp
Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Oncology Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Oral Biologics And Biosimilars Market 2026
https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model